Sustained Or Differential Release Type Patents (Class 424/468)
  • Patent number: 12016851
    Abstract: The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: June 25, 2024
    Assignees: Chiesi Farmaceutici S.p.A., Università degli Studi di Milano
    Inventors: Marisa Pertile, Andrea Gazzaniga, Matteo Cerea, Micol Cirilli
  • Patent number: 11992558
    Abstract: The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free.
    Type: Grant
    Filed: July 21, 2019
    Date of Patent: May 28, 2024
    Inventor: Sushma Paul Berlia
  • Patent number: 11986451
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: May 21, 2024
    Assignee: Flamel Ireland Limited
    Inventors: Claire Mégret, Hervé Guillard, Jean-François Dubuisson
  • Patent number: 11980665
    Abstract: A method of cancer hyperthermia therapy includes placing a device including an exogenously-excitable polymeric material at a cancer hyperthermia therapy site of a patient. The method also includes supplying an exogenous energy to the device such that the exogenous energy excites the exogenously-excitable polymeric material at the cancer hyperthermia therapy site to heat the cancer hyperthermia therapy site to a hyperthermia temperature. A method of preparing a polymeric material includes combining an alcohol monomer, a seed of the polymeric material, and an aqueous liquid in a vessel. The method also includes adding an acid monomer to the vessel and supplying an exogenous energy to the vessel. The polymeric material is exogenously excited by the exogenous energy to heat the polymeric material. The method further includes removing water from the vessel and producing the polymeric material, which is a polyester, in the vessel.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: May 14, 2024
    Assignee: THE SECANT GROUP, LLC
    Inventors: Peter D. Gabriele, Jared Ely, Jeremy J. Harris
  • Patent number: 11939612
    Abstract: The invention provides a process for preparing sphingolipids, compositions comprising sphingolipids and further components, and for the use of the compositions.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 26, 2024
    Assignee: Evonik Operations GmbH
    Inventors: Marrit Friederike Eckstein, Monica Desiree van Logchem, Hans Henning Wenk, Annika Schrader, Ursula Maczkiewitz, Claudia Hierath, Sunay Karacocuk, Andreas Seifert
  • Patent number: 11911510
    Abstract: The invention relates to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation. The extended release matrix formulation comprises (1) at least one active agent, (2) at least one anionic surfactant, and (3) at least about 40% by weight (based on the weight of the extended release matrix formulation) of at least one polyethylene oxide. In certain embodiments, the molar ratio of the at least one anionic surfactant to the at least one active agent is from about 1:2 to about 10:1.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 27, 2024
    Assignee: Purdue Pharma L.P
    Inventors: Ozgur Akcan, Richard Mannion
  • Patent number: 11896722
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 13, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 11883405
    Abstract: The present invention relates to a pharmaceutical product comprising a combination of methotrexate and novobiocin, or any pharmaceutically acceptable salts of said compounds, and a pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent. The invention further relates to a use of the pharmaceutical product and composition in therapy, such as prevention, progression prophylaxis and/or treatment of autoimmune diseases.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: January 30, 2024
    Assignee: AMPLIO PHARMA AB
    Inventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
  • Patent number: 11857559
    Abstract: The present invention relates to a binder free stable pharmaceutical composition comprising amorphous canagliflozin or a pharmaceutically acceptable salt or a prodrug thereof, and one or more pharmaceutically acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical stability, polymorphic stability & comparative dissolution and bioavailability profile to that of INVOKANA® tablets.
    Type: Grant
    Filed: November 21, 2020
    Date of Patent: January 2, 2024
    Inventors: Satyabrata Barik, Venugopala Chokkasandra Jayarama Reddy, Sivakumaran Meenakshisunderam
  • Patent number: 11850225
    Abstract: Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: December 26, 2023
    Assignee: AMNEAL PHARMACEUTICALS LLC
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, David Penake, Wolfgang Mohr, Manuel Weinheimer
  • Patent number: 11819569
    Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 21, 2023
    Assignee: VECTURA INC.
    Inventor: Kambiz Yadidi
  • Patent number: 11786526
    Abstract: The invention relates to a pharmaceutical composition comprising the active ingredients rosuvastatin of formula I, with the systematic name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid or its pharmaceutically acceptable salts, esters, hydrates or solvates, and ezetimibe of formula II, with the systematic name (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one or its pharmaceutically acceptable salts, esters, hydrates or solvates, as well as a preparation method of this pharmaceutical composition. The weight ratio of the layers is 1:2 to 2:1.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 17, 2023
    Assignee: SANOFI
    Inventors: Alena Prokopova, Jaroslava Svobodova, Ondrej Dammer, Petr Mikes
  • Patent number: 11771705
    Abstract: The present invention relates to the field of prostate cancer treatment, and in particular the field of prostate cancer treatment by Androgen Deprivation Therapy (ADT). The present treatment involves oral administration of an estetrol component in conjunction with ADT.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 3, 2023
    Assignee: FUND SA
    Inventor: F. M. J. Debruyne
  • Patent number: 11759416
    Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
    Type: Grant
    Filed: January 17, 2022
    Date of Patent: September 19, 2023
    Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.
    Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
  • Patent number: 11752094
    Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: September 12, 2023
    Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.
    Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
  • Patent number: 11746174
    Abstract: A biodegradable polyester is provided. The biodegradable polyester is a transesterification or esterification reaction product of a reactant (a) and a reactant (b). The reactant (a) is a modified linear saccharide oligomer. The reactant (b) is a polyester, or the reactant (b) includes a dicarboxylic acid and a diol. The modified saccharide oligomer is a reaction product of a saccharide oligomer and a modifier.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: September 5, 2023
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Shu-Jiuan Huang, Shin-Liang Kuo, Hung Ming Chang, Sheng-Lung Chang, Jin-An Wu
  • Patent number: 11737985
    Abstract: An oral dosage formulation having one or more active pharmaceutical ingredients (APIs) or pharmaceutically acceptable salts thereof, 27 wt % to 34 wt % of hydroxypropyl methyl cellulose, 25 wt % to 53 wt % of high-density microcrystalline cellulose having a particle size of 50 micrometers to 100 micrometers, and 6.5 wt % to 8 wt % of lactose monohydrate. A non-exhaustive list of APIs that may be used in the oral dosage formulation includes: hydralazine or a pharmaceutically acceptable salt thereof; naltrexone or a pharmaceutically acceptable salt thereof; prazosin or a pharmaceutically acceptable salt thereof; torsemide or a pharmaceutically acceptable salt thereof; and aldosterone receptor antagonist(s) (e.g., spironolactone or eplerenone) or a pharmaceutically acceptable salt thereof. The formulations are used to treat disorders, including, but not limited to, heart failure-associated sleep apnea, uncontrolled or resistant hypertension, Crohn's disease, and systemic inflammation.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: August 29, 2023
    Inventor: Salim Shah
  • Patent number: 11730702
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: August 22, 2023
    Assignee: Clexio Biosciences, Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
  • Patent number: 11712418
    Abstract: A chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: August 1, 2023
    Assignees: BRUIN BIOSCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: James Na, David Imagawa, Fabio Tucci, Graham Beaton, Satheesh Ravula
  • Patent number: 11701350
    Abstract: The invention is directed to pharmaceutical compositions comprising dextromethorphan and methods of use thereof. Formulations of the present invention include dextromethorphan or a pharmaceutically acceptable salt thereof in a sustained release formulation comprising a controlled release agent. Formulations of the present invention include a core tablet, optionally an active coating and, optionally a film coating. The pharmaceutical compositions may be used as an antitussive, and the invention further relates to the treatment of cough in a patient in need thereof.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: July 18, 2023
    Assignee: L. PERRIGO COMPANY
    Inventors: Kiran Kumar Muppireddy, Inderdeep Singh Bhatia, Eric Cristopher Pattok, Carlos O. Paz, Bruce Duane Johnson, Lisa Kay Lupton
  • Patent number: 11696894
    Abstract: Described herein are an aspirin or active aspirin derivative and a COX-2 inhibitor, at least one of which has an enteric or partial enteric coating, administered in combination yet delivered sequentially, for the treatment and prophylactic treatment of diseases, symptoms and conditions. In some embodiments, the COX-2 inhibitor has the enteric coating; however, the aspirin or active aspirin derivative may additionally or alternately have the enteric coating. In all embodiments, the drug having the enteric coating or enteric formulation is targeted for absorption in the small intestine or colon, or both the small intestine and the colon.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: July 11, 2023
    Assignee: Celsprin LLC
    Inventor: Peter Van Patten
  • Patent number: 11696959
    Abstract: The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer. Also provided are unmodified cisplatin molecules encapsulated by silica nanoparticles, and their use in the treatment of cancer.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: July 11, 2023
    Assignee: CITY OF HOPE
    Inventors: Pengpeng Cao, Jacob Berlin, Karen Aboody, Rachael Mooney, Wafa Abidi
  • Patent number: 11690806
    Abstract: An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of the hydrophobic polymer to the hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 4, 2023
    Assignee: Celanese EVA Performance Polymers LLC
    Inventor: Christian Schneider
  • Patent number: 11602512
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Patent number: 11602513
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Patent number: 11571391
    Abstract: The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.
    Type: Grant
    Filed: December 25, 2018
    Date of Patent: February 7, 2023
    Assignee: Triastek, Inc.
    Inventors: Feihuang Deng, Xiaoling Li, Senping Cheng, Ying Wang, Qing Luo
  • Patent number: 11554114
    Abstract: An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: January 17, 2023
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, Robert Barnett Jones
  • Patent number: 11534414
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: December 27, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11517543
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 6, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11471674
    Abstract: Apparatuses and methods for electrokinetic transport of fluids to patients. Drug-containing solutions may be placed in vial-like reservoir, which is connected to an apparatus such as a traditional catheter or other device capable of holding a drug-containing solution. Instead of a vial-like reservoir, a doped infusion pad or a gel may be used as a source of the drug-containing solution. The reservoir and apparatus may thus be the same component. The methods and apparatuses disclosed herein may also be used to transport fluid alone to achieve a clinical effect. The apparatus is placed at the point of drug delivery. The counter-electrode may be placed in or on a patient. Current is passed from the reservoir to the counter-electrode. Through electrokinetic transport, drug-containing solution is delivered along a current path from the drug source to the counter-electrode. A hollow fiber catheter for use in electrokinetic transport is also disclosed.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: October 18, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen Weber, Amir H. Faraji, Yifat Guy, Andrea Jaquins-Gerstl, Alec C. Valenta
  • Patent number: 11433058
    Abstract: An oral solid non-pulsatile 24 hours prolonged-release composition including an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochloride, together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour; from 35% to 45% by weight of betahistine is dissolved in 2 hours; from 46% to 60% by weight of betahistine is dissolved in 4 hours; from 61% to 80% by weight of betahistine is dissolved in 8 hours; from 81% to 97% by weight of betahistine is dissolved in 16 hours; and from 98% to 100% by weight of betahistine is dissolved in 24 hours. It also relates to the treatment of a vestibular disease or condition, more particularly in the treatment of Ménière's disease.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 6, 2022
    Assignee: INTAS PHARMACEUTICALS LTD.
    Inventors: Himanshukumar Dasharathlal Patel, Vinod Purushottam Dube, Venkataramana Naidu, Sunil Shantwan Borude
  • Patent number: 11426388
    Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 30, 2022
    Assignee: Romark Laboratories L.C.
    Inventors: Jean-Francois Rossignol, Marc Ayers
  • Patent number: 11400064
    Abstract: There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: August 2, 2022
    Assignee: Cereno Scientific AB
    Inventors: Sverker Jern, Jonas Faijerson Saljo, Niklas Bergh
  • Patent number: 11395808
    Abstract: There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: July 26, 2022
    Assignee: Cereno Scientific AB
    Inventors: Nils Ove Gustafsson, Hans Roger Marcus Martensson, Niklas Bergh, Jonas Faijerson Saijo, Sverker Jern
  • Patent number: 11351213
    Abstract: The present invention relates to a composition comprising or, alternatively, consisting of an effective amount of a mixture which comprises at least, or consists of: a) an extract of Pelargonium sidoides; b) an extract of Adhatoda vasica; and c) N-acetyl cysteine for use in a method for the preventive or therapeutic treatment of at least one respiratory tract disorder in a subject, wherein said treatment method comprises the administration of said composition to the subject.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: June 7, 2022
    Assignee: NEILOS S.R.L.
    Inventor: Umberto Di Maio
  • Patent number: 11344494
    Abstract: The present invention provides an impregnated porous carrier material comprising at least one active pharmaceutical ingredient (API) impregnated throughout the internal surface of a porous carrier. The present invention further provides immediate release and sustained release pharmaceutical dosage forms comprising the impregnated porous carrier material disclosed herein such that any single active pharmaceutical ingredient (API) content variability in the finished drug product has a relative standard deviation of less than 3%.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: May 31, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Fernando J. Muzzio, Benjamin J. Glasser, Plamen I. Grigorov
  • Patent number: 11331281
    Abstract: Mixture of stabilised biologically available curcumin for orodispersible formulations, formulations of biologically available curcumin and orodispersible tablet with biologically available curcumin and its application. An orodispersible tablet with biologically available curcumin contains particles of extract of rhizome of plant Curcuma longa, which contains, at least, 95% by weight of curcumin, grounded to size 100 to 250 nm in mixture with mannitol in weight ratio 1 to 3:1 (mannitol:curcumin). Orodispersible tablet also contains an orodispersible carrier, and curcumin 100% biologically available through oral mucosa.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: May 17, 2022
    Inventors: Jan Stonis, Ivan Mikes, Andrea Dolezalova, Jarmila Kralova, Milan Jakubek, Pavel Martasek, Vladimir Kral
  • Patent number: 11311488
    Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: April 26, 2022
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita
  • Patent number: 11304906
    Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: April 19, 2022
    Assignee: XWPHARMA LTD.
    Inventors: Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Nicolas D. Kirkland
  • Patent number: 11241377
    Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: February 8, 2022
    Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.
    Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
  • Patent number: 11229619
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: January 25, 2022
    Assignee: Biogen Swiss Manufacturing GmbH
    Inventors: Henrik Nilsson, Bernd W. Mueller
  • Patent number: 11224615
    Abstract: Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe2+ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: January 18, 2022
    Assignee: SOLVOTRIN THERAPEUTICS LTD
    Inventors: John Gilmer, Radics Gabor, Michael Whelehan, Jun Wang, Pat O'Flynn, Mark Ledwidge
  • Patent number: 11207271
    Abstract: The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: December 28, 2021
    Assignee: NLS Pharmaceutics AG
    Inventors: Alexander C. Zwyer, Lewis P. Amsel, Virginia Schmith, Scott Brantley
  • Patent number: 11173148
    Abstract: The present invention relates to a sustained-release pharmaceutical composition intended for animal use, which comprises a drug, a sugar, a wax, and a water-soluble polymer.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 16, 2021
    Assignee: DS PHARMA ANIMAL HEALTH CO., LTD.
    Inventor: Teruaki Kuriyama
  • Patent number: 11147273
    Abstract: The present invention encompasses a stabilized parasiticidal granule composition comprising a macrocyclic lactone compound and an insect growth regulator. The invention also encompasses methods of making and methods of using the granule for treating, controlling or preventing parasitic infestation or parasitic infection in an animal.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 19, 2021
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Kour Chand Jindal, Jian Han, Kim Agnew
  • Patent number: 11135175
    Abstract: A microcapsule includes an active component encapsulated within a polymerized hydrolyzed protein shell. The microcapsule has an average diameter that is less than one hundred micrometers as determined by a laser diffractometer.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: October 5, 2021
    Assignee: Anabio Technologies Limited
    Inventor: Sinead Doherty
  • Patent number: 11129837
    Abstract: A liquid composition contains a salicylate compound (e.g. aspirin), glycerin triacetate, saccharin. The salicylate compound is soluble in the composition, which is particularly suitable for oral, parenteral or pulmonary administration.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 28, 2021
    Assignee: INNOVATE PHARMACEUTICALS LIMITED
    Inventors: Simon Jason Cohen, Craig Hurst
  • Patent number: 11123331
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 21, 2021
    Assignee: VELOXIS PHARMACEUTICALS, INC.
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11110081
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 7, 2021
    Assignee: VELOXIS PHARMACEUTICALS, INC.
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11111400
    Abstract: Some embodiments are directed to a multimaterial powder used in the field of metallurgy and plasturgy. The multimaterial powder includes support particles having a median particle size distribution between 1 ?m and 100 ?m and functionalising particles having a median particle size distribution that is a factor of 10 to 1000 lower relative to the support particles. The powder is characterised in that the support particles and the functionalising particles form composite grains having a core-shell structure that each have a core formed by a support particle, and a shell, that covers between 10 and 100% of the surface of the support particle and which is formed by at least one surface layer of the functionalising particles.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 7, 2021
    Assignee: H.E.F.
    Inventors: Constantin Iacob, Sébastien Bucher, Fabrice Prost, Christophe Heau